Guardian Bio logo

Guardian BioDendritic cell-based platform for cancer therapy

Your immune system is your body’s best weapon and defense against cancer. It is only when it is overcome that cancer develops into full blown disease. Dendritic cells sit at the helm of the immune system, directing and dictating immune responses. Data has shown dendritic cells are often dysfunctional in cancer patients, and that this dysfunction is a bottleneck for other therapies. Guardian Bio’s approach is focused on creating a dendritic cell-based product which drives anti-tumor activity through activating the killers of the immune system AND training them against multiple cancer targets. We take stem cells from cancer patients, turn them into specific therapeutic dendritic cells specially trained against that patient’s tumor, and re-introduce them back into the body. Our therapeutic dendritic cells revitalize the killers of the immune system and give them the kickstart they need to fight - and win - against cancer.

2022-07-06
Active
Early
S22
2
Healthcare
United States of AmericaAmerica / Canada
Guardian Bio screenshot
More About Guardian Bio

Guardian Bio: Reinventing Dendritic Cell Therapy for Solid Tumors

Introduction

At Guardian Bio, we are combining regenerative medicine with immunotherapy to restore anti-cancer immunity in late-stage solid tumor patients.

Key Features

  • Proprietary process to generate true cDC1s from a patient’s own stem cells
  • Guard-cDC1s capable of restoring dysfunctional antigen presentation
  • Ability to stimulate against multiple targets simultaneously
  • Activation of various effector cells

Use Cases

  • Late-stage solid tumor patients
  • Patients with compromised cancer immunity
  • Clinical settings requiring advanced immunotherapy solutions

Pricing

Contact us for detailed pricing information tailored to your specific needs and treatment plans.

Teams

Founders

  • Ananya Zutshi, MS, MBA: Co-Founder & CEO, with extensive experience in pharma/biotech industry roles across Operations, Engineering, Business Development, and Project Management.
  • Richard Barrett, PhD: Co-Founder & CSO, with a background in marine biology, immunology, and cancer immunology research.
  • Karolina Palucka, MD, PhD: Academic Co-Founder & Chair, Scientific Advisory Board, a world-renowned clinical oncologist and cancer immunologist.

Advisors & Consultants

  • Tony Polverino, PhD: Former CSO, Kite Pharma
  • Jessica Fletchner, PhD: Former CSO, Genocea
  • Scott Antonia, MD, PhD
  • Lisa Coussens, MD (hc), PhD: Former AACR President, Deputy Director for Basic & Translational Research, Knight Cancer Institute
  • Max Krummel, PhD: UCSF Professor, Founder and Partner at Foundery LP

Guardian Bio is dedicated to pioneering advancements in cancer immunotherapy, leveraging cutting-edge science to bring life-changing therapies to patients.